Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Medical & Biological Engineering & Computing|August 30, 2017
Apnea and heart rate detection from tracheal body sounds for the diagnosis of sleep-related breathing disordersChristoph Kalkbrenner, Manuel Eichenlaub, Stefan Rüdiger, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|September 2, 2017
Validation of a New System Using Tracheal Body Sound and Movement Data for Automated Apnea-Hypopnea Index EstimationChristoph Kalkbrenner, Manuel Eichenlaub, Stefan Rüdiger, et al.
Lung Cancer (Amsterdam, Netherlands)|September 1, 2023
Immune checkpoint inhibitors in non-small cell lung cancer - When should we dare to stop treatment?Farastuk Bozorgmehr, Annette Müller, Justyna Rawluk, et al.
Respiratory Care|September 25, 2014
Relation of exercise capacity with lung volumes before and after 6-minute walk test in subjects with COPDThomas Wibmer, Stefan Rüdiger, Cornelia Kropf-Sanchen, et al.
Multidisciplinary Respiratory Medicine|March 21, 2013
Isolated IgG4-related interstitial lung disease: unusual histological and radiological features of a pathologically proven caseThomas Wibmer, Cornelia Kropf-Sanchen, Stefan Rüdiger, et al.
Blood Pressure|August 20, 2015
Blood pressure monitoring during exercise: comparison of pulse transit time and volume clamp methodsThomas Wibmer, Coy Denner, Christoph Fischer, et al.
Pneumologie (Stuttgart, Germany)|December 6, 2024
[Neoadjuvant therapy for resectable non-small cell lung cancer]Katrin Welcker, Danny Jonigk, Cornelia Kropf-Sanchen, et al.
Respiratory Care|October 31, 2013
Effects of nasal positive expiratory pressure on dynamic hyperinflation and 6-minute walk test in patients with COPDThomas Wibmer, Stefan Rüdiger, Claudia Heitner, et al.
Nuklearmedizin. Nuclear Medicine|September 11, 2023
Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLCKatharina Deininger, Joel Niclas Raacke, Elham Yousefzadeh-Nowshahr, et al.
Oncology Research and Treatment|September 12, 2016
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, et al.
Pageof 3